Rectal Cancer: Scratch to Pro

1. ANATOMY - The Foundation of Everything

What Is the Rectum?

• Upper rectum (10-15 cm from anal verge): above the peritoneal reflection, behaves more like sigmoid
• Mid rectum (5-10 cm): extraperitoneal, no covering serosa, high local recurrence risk
• Lower rectum (<5 cm): proximity to sphincters, challenges sphincter preservation

Borders of the Rectum in the Pelvis

• Lateral: pelvic sidewall
• Posterior: sacrum
• Anterior (men): prostate, seminal vesicles, bladder
• Anterior (women): vagina, uterus, bladder

Vascular Supply

• Superior rectal artery - terminal branch of the inferior mesenteric artery (IMA) - supplies upper 2/3 of rectum
• Middle rectal artery - from internal iliac - supplies lower rectum
• Inferior rectal artery - from internal pudendal - supplies anal canal

Fascial Planes - The Holy Grail of Rectal Surgery

Clinical pearl: Dissecting deep to the presacral fascia causes catastrophic hemorrhage from the presacral venous plexus - torn vessels retract into the sacral foramina and are nearly impossible to control.

Autonomic Nerves - Functional Anatomy

• Hypogastric nerves (sympathetic, L1-L3): descend from the superior hypogastric plexus at the sacral promontory - vulnerable during IMA ligation and presacral dissection
• Pelvic splanchnic nerves (parasympathetic, S2-S4): emerge from the pelvic sidewall, join hypogastric nerves to form the inferior hypogastric plexus at the pelvic sidewall - vulnerable during lateral dissection
• Neurovascular bundles (Walsh's bundles): run along the posterolateral surface of the prostate - vulnerable during anterior dissection

2. EPIDEMIOLOGY & RISK FACTORS

• Approximately 46,050 new rectal cancer cases diagnosed annually in the USA (2023 data)
• Rectal cancers now represent 31% of all colorectal cancers (up from 27% in 1995)
• Young-onset rectal cancer is rising: ~2% per year increase in patients under 50
• 3rd most common cause of cancer death in women; 2nd most common in men

Risk Factors

• Age (peak 60-70s, but rising in younger patients)
• Personal/family history of colorectal polyps or CRC
• Hereditary syndromes: Lynch syndrome (MLH1, MSH2, MSH6, PMS2 mutations - mismatch repair deficiency/MSI), FAP (APC mutation), MYH-associated polyposis
• Inflammatory bowel disease (especially ulcerative colitis)
• Diet: low fiber, high processed/red meat
• Obesity, physical inactivity, alcohol, smoking

3. MOLECULAR PATHOGENESIS

Chromosomal Instability (CIN) - 65-70% of CRC

• Classic adenoma-carcinoma sequence (Fearon-Vogelstein model)
• Begins with APC gene mutation → disrupts Wnt signaling → nuclear β-catenin accumulation → dysplastic proliferation (tubular adenoma)
• Progression: APC → KRAS mutation (growth promotion) → TP53/SMAD4/PIK3CA/FBXW7 mutations (invasion)
• Most CIN tumors have APC mutation in 80% of cases

Serrated (Methylator/CIMP) Pathway - 15-20%

• Begins with BRAF mutation
• CpG island methylation silences tumor suppressor genes
• Produces sessile serrated lesions and traditional serrated adenomas
• Associated with MLH1 methylation → MSI-high tumors

Microsatellite Instability (MSI) - 15%

• Defective mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2)
• Can be somatic (sporadic - often from MLH1 promoter methylation) or germline (Lynch syndrome)
• MSI-H tumors respond dramatically to PD-1 immune checkpoint inhibitors - clinically crucial

4. CLINICAL PRESENTATION

• Rectal bleeding (bright red blood per rectum)
• Iron deficiency anemia
• Change in stool caliber
• Tenesmus and rectal pain - late findings, indicative of locally invasive tumor
• Palpable rectal mass on DRE
• Neuropathic pain - indicates sacral nerve root invasion

Remember: Tenesmus + rectal pain = alarm signs for locally advanced, often low-lying tumor.

5. CLINICAL EVALUATION & STAGING

Step 1: History and Physical

• Bowel, urinary, and sexual baseline function (critical for surgical planning and prognostication of post-op quality of life)
• Family history (hereditary syndromes?)
• Medical fitness and frailty (guides ability to tolerate neoadjuvant therapy)

• Distance from the anal verge and dentate line
• Mobility of tumor relative to prostate/vagina/sphincter complex
• Sphincter tone and baseline continence

Key point: Rigid proctoscopy (not flexible endoscopy) is the gold standard for measuring distance from anal verge. On rigid scope, tumors within 12-15 cm = rectal cancers.

Step 2: Colonoscopy

Step 3: Laboratory

• CEA (baseline, not diagnostic - used for prognosis and surveillance)
• Routine CBC, metabolic panel
• MMR/MSI testing by IHC - essential; MSI-H tumors have different treatment implications (immunotherapy responsiveness)

Step 4: Imaging

• T stage (depth of wall penetration)
• N stage (abnormal nodes in mesorectum)
• Circumferential Resection Margin (CRM) - if tumor is within 1-2 mm of the mesorectal fascia, CRM is threatened/positive → strongly predicts local recurrence → drives need for neoadjuvant therapy
• Location relative to the peritoneal reflection
• EMVI (extramural vascular invasion) - important prognostic factor

Step 5: TNM Staging (AJCC 8th Edition)

• T1: into submucosa
• T2: into muscularis propria
• T3: through muscularis propria into pericolorectal tissues (mesorectal fat)
• T4a: penetrates visceral peritoneum (upper rectum)
• T4b: invades adjacent organ/structure

• N0: no regional nodes
• N1: 1-3 positive nodes (N1a=1, N1b=2-3, N1c=tumor deposits)
• N2: 4+ positive nodes (N2a=4-6, N2b=7+)

• M0: no distant metastasis
• M1a: one site/organ
• M1b: two+ sites/organs
• M1c: peritoneal metastasis

• Stage I: T1-2N0M0
• Stage II: T3-4N0M0 (IIA=T3, IIB=T4a, IIC=T4b)
• Stage III: any T, N1-2, M0
• Stage IV: any T, any N, M1

Step 6: Multidisciplinary Tumor Board

6. TREATMENT OVERVIEW

cT1-2 N0  →  Surgery first (TME or local excision for selected T1)
cT3-4 or N+  →  Neoadjuvant therapy THEN surgery (± adjuvant therapy)
Stage IV  →  Systemic therapy + selective surgery
MSI-H (any stage)  →  Consider immunotherapy first

7. SURGICAL ANATOMY AND THE PRINCIPLE OF TME

• Traditional blunt dissection: 25% positive CRM, very high recurrence
• Norwegian cohort of 3,319 patients after TME implementation: local recurrence dropped from 12% to 6%, survival increased from 60% to 73%

• T1-T2: ~10%
• T3N0: 15-35%
• T3-4 node-positive: 45-65%

8. SURGICAL PROCEDURES

A. Low Anterior Resection (LAR)

1. Mobilize the left colon by dividing the left lateral peritoneal attachments
2. Divide IMA: either high ligation (at IMA origin - needed for bulky adenopathy, improves reach) or low ligation (just distal to left colic artery, preserving it). High ligation is NOT automatically required; low ligation preserves left colic artery blood supply for anastomosis
3. Mobilize mesorectum posteriorly in the holy plane (sharp dissection, not blunt)
4. Divide Denonvilliers' fascia anteriorly (or go anterior to it to protect prostate/vagina)
5. Complete lateral dissection, protecting pelvic autonomic nerves
6. Divide the bowel distally with adequate margin + complete mesorectum
7. Anastomosis (colorectal or coloanal): stapled (double-stapling technique most common) or hand-sewn

B. Abdominoperineal Resection (APR)

• Tumor involves the sphincter complex
• Locally advanced low tumor where adequate distal margin cannot be achieved
• Poor preoperative bowel function (end colostomy preferred over a leaking low anastomosis)

Decision between LAR and APR: The key question is whether a negative distal margin and functional sphincter can be achieved. Neoadjuvant therapy has expanded the population eligible for sphincter-preserving LAR.

C. Local Excision

• cT1N0, without high-risk features
• High-risk features that EXCLUDE local excision: deep SM invasion (Kikuchi SM3, >1 mm submucosal), poor differentiation, lymphovascular invasion (LVI), perineural invasion (PNI), tumor budding, positive margins

• Transanal excision (TAE): conventional, limited to low tumors
• Transanal Endoscopic Microsurgery (TEM): endoscopic platform, allows higher rectal access, full-thickness en bloc excision
• Transanal Minimally Invasive Surgery (TAMIS): uses standard laparoscopic port system transproctally - more widely available than TEM

D. IMA Ligation Level

• High ligation: at aortic origin of IMA - needed for bulky N2 disease, improves colonic reach
• Low ligation: just distal to left colic artery - preserves left colic blood supply
• The inferior mesenteric vein (IMV) is separately divided

E. Minimally Invasive Approaches

• Laparoscopic TME: improved short-term outcomes (earlier recovery, less blood loss), but RCTs (COLOR II, ACOSOG Z6051, ALaCaRT) failed to prove oncologic non-inferiority to open surgery. Still recommended by NCCN but only by experienced surgeons
• Robotic TME: improved visualization and maneuverability in the narrow pelvis; current guidelines support its use
• Transanal TME (taTME): bottom-up approach via transanal platform - particularly useful for low tumors, narrow pelvis, obesity; improves distal margin access

9. NEOADJUVANT THERAPY

Why Neoadjuvant?

Critical distinction: Neoadjuvant therapy is for extraperitoneal rectal cancers because these have no serosa and thus high local recurrence risk. Upper rectal cancers at or above the peritoneal reflection behave more like colon cancers and are NOT treated with neoadjuvant radiation.

Landmark Trials

• Compared preoperative chemoRT (50.4 Gy/28 fractions + infusional 5-FU) vs. postoperative chemoRT for cT3-4 or N+
• No difference in OS (~60% at 10 years)
• But neoadjuvant was BETTER in:
  • Local recurrence: 6% vs 13% (p<0.001)
  • Tumor downstaging and downsizing
  • Sphincter preservation rate: 39% vs 19% for low tumors
  • Toxicity: less acute and late toxicity with neoadjuvant therapy
• Result: neoadjuvant chemoRT became the standard

• Compared short-course RT (5x5 Gy) + consolidation chemotherapy vs. long-course chemoRT
• Short-course RT + consolidation CAPOX: better pathologic complete response rates and disease-free survival

• Total neoadjuvant therapy (TNT) with induction FOLFIRINOX → chemoRT → surgery vs. chemoRT alone → surgery
• TNT arm: significantly better pCR rates (~28% vs ~12%), better disease-free survival
• Established TNT as a valid approach for high-risk locally advanced rectal cancer

Radiation Regimens

Total Neoadjuvant Therapy (TNT) - The Modern Standard

• Full-dose systemic chemotherapy given upfront (not after) - better tolerated, no post-op delays
• Higher rates of pathologic complete response (pCR)
• Better distant disease control
• Enables organ preservation in responders

1. Induction chemo → chemoRT → surgery (PRODIGE 23 approach)
2. SCRT → consolidation chemo → surgery (RAPIDO approach)

2024 ASCO Guideline (PMID 39116386): recommends TNT as preferred approach for locally advanced rectal cancer with high-risk features (T4, threatened CRM, N2, EMVI).

10. WATCH-AND-WAIT / ORGAN PRESERVATION

• Endoscopy: no visible tumor (white scar only)
• DRE: no palpable tumor
• MRI: no residual signal/mass
• ALL THREE criteria must be met

• Regrowth rate: ~20-25% (usually within 1-2 years)
• Regrowth is almost exclusively luminal and salvageable with surgery
• Overall survival is equivalent to surgery in properly selected patients

Key principle: MSI-H/dMMR rectal cancers have very high complete response rates to PD-1 immunotherapy (dostarlimab/pembrolizumab) - in the NICHE trial and Cercek 2022 study, 100% clinical response rates were achieved with pembrolizumab in cT2-4 dMMR rectal cancer, with many achieving sustained cCR without surgery.

11. STAGING AND PROGNOSIS (PATHOLOGIC)

• T stage (depth of invasion)
• N stage (number of nodes examined, number positive - minimum 12 nodes required for adequate staging)
• M stage
• Circumferential Resection Margin (CRM): positive if tumor within 1 mm of mesorectal fascia - most important local recurrence predictor
• Distal Resection Margin
• Tumor regression grade (TRG): Mandard or Ryan grading of response to neoadjuvant therapy
• LVI, PNI, tumor budding
• MMR/MSI status
• KRAS, NRAS, BRAF mutation status (for stage IV patients, guides targeted therapy)

• Stage I: ~90%
• Stage II: ~70-80%
• Stage III: ~50-60%
• Stage IV (metastatic): ~10-15% (but selected resectable liver metastases: up to 71%)

• pCR rate with long-course CRT: ~15-20%
• pCR rate with TNT: ~25-30%
• pCR is a strong predictor of improved long-term outcomes

12. ADJUVANT THERAPY

• Patients who received full TNT with pathologic stage II-III disease: no adjuvant chemotherapy needed
• Patients with clinical/pathologic stage II-III who did NOT receive full neoadjuvant chemotherapy: adjuvant chemotherapy recommended
• Preferred regimen: FOLFOX x 8 cycles (oxaliplatin + 5-FU/leucovorin); can omit oxaliplatin in clinical T3N0
• Adjuvant radiotherapy: given selectively to patients with path stage II-III who did NOT receive neoadjuvant radiation AND are at increased risk for local recurrence

13. SYNCHRONOUS METASTATIC DISEASE (Stage IV)

• Liver is most common site (also lung - more common in rectal than colon cancer)
• ~50% of stage IV patients have liver-only disease
• Liver-only, resectable metastases: 5-year OS up to 71% with chemotherapy + surgery
• Management requires MDT discussion assessing resectability

1. Simultaneous resection of rectum + liver
2. Colorectal-first: resect primary → chemotherapy → liver resection
3. Liver-first: if primary is not immediately obstructing, resect liver first (reduces risk of progression of limiting disease), then chemo, then rectal surgery

• FOLFOX or FOLFIRI + bevacizumab (anti-VEGF) for first-line RAS-mutant or unknown
• Add cetuximab or panitumumab (anti-EGFR) for wild-type KRAS/NRAS/BRAF tumors (left-sided predominance)
• BRAF V600E mutant: doublet chemo + BRAF/MEK inhibitors (encorafenib)
• MSI-H/dMMR: pembrolizumab or nivolumab - dramatically superior to chemotherapy (KEYNOTE-177 trial)

14. LOCALLY RECURRENT RECTAL CANCER

• Always re-biopsy for confirmation and MSI/dMMR testing
• MDT evaluation for resectability
• If no prior radiation: neoadjuvant chemoRT → pelvic exenteration if resectable
• Potentially involves: posterior exenteration (rectum + bladder/prostate), total pelvic exenteration, sacrectomy
• Soft tissue flap (VRAM, gracilis, omentoplasty) reconstruction is often required for large perineal defects
• R0 resection: only chance of cure; 5-year OS ~30-40% after R0 pelvic exenteration

15. POSTOPERATIVE SURVEILLANCE

• H&P + CEA: every 3-6 months for 2 years, then every 6 months for 5 years total
• CT chest/abdomen/pelvis: every 6-12 months for 5 years
• Colonoscopy: 1 year after surgery (if no preoperative colonoscopy done), then every 3-5 years
• Stage I: no imaging or tumor marker follow-up recommended

16. SPECIAL SCENARIOS & HIGH-YIELD EXAM POINTS

17. QUICK MEMORY FRAMEWORK

RECTAL CANCER MANAGEMENT ALGORITHM

Diagnosis:  Biopsy (adenocarcinoma) + CEA + colonoscopy + MMR/MSI
Staging:    Pelvic MRI + CT C/A/P
            → cT1-2 N0: Surgery first
            → cT3-4 or N+, extraperitoneal: Neoadjuvant (TNT preferred) → surgery
            → MSI-H: Consider pembrolizumab ± W&W
            → Metastatic: MDT → resectable vs unresectable pathway

Surgery:    LAR (sphincter-preserving) vs APR (sphincter-sacrificing)
            ALWAYS TME (the holy plane)
            IMA ligation (high vs low) + IMV division
            Colorectal/coloanal anastomosis ± diverting ileostomy

Path:       CRM (most important) + pCR + TRG + MMR + KRAS/NRAS/BRAF (stage IV)

Adjuvant:   If TNT given → no adjuvant chemo
            If no prior full systemic chemo → FOLFOX x 8 cycles

Surveillance: CEA + CT q6-12mo x 5yr; colonoscopy 1yr